Want to see ZNTL full AI Analyst Report?
Top Page
Zentalis Pharmaceuticals
(NASDAQ:ZNTL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.00
▼(-48.45% Downside)
Action:Reiterated
Date:10/20/26
The score is held down primarily by weak financial performance (ongoing losses and recurring cash burn with a shrinking equity base) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to anchor due to the negative P/E, while corporate events modestly offset risk by improving funding/visibility via a large equity raise and pipeline progress.
Positive Factors
Pipeline Progress
Azenosertib has advanced into late-stage development, with key enrollment milestones completed and a Phase 3 confirmatory study initiated. This progress improves the pipeline’s regulatory and commercial potential, while the FDA meeting outcome supports the selected dosing and study strategy.
Negative Factors
No Recurring Product Revenue
Zentalis remains dependent on clinical development rather than an established commercial product franchise, leaving product revenue and operating income unproven. Until a candidate is approved and launched, the business has limited internal funding capacity and relies on external capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Progress
Azenosertib has advanced into late-stage development, with key enrollment milestones completed and a Phase 3 confirmatory study initiated. This progress improves the pipeline’s regulatory and commercial potential, while the FDA meeting outcome supports the selected dosing and study strategy.
Read all positive factors
Zentalis Pharmaceuticals (ZNTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$188.40M
Dividend YieldN/A
Average Volume (3M)1.36M
Price to Earnings (P/E)―
Beta (1Y)3.41
Revenue Growth-100.00%
EPS Growth14.08%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.46
Shares Outstanding94,671,910
10 Day Avg. Volume1,396,403
30 Day Avg. Volume1,364,134
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.38K
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$7.50Price Target Upside93.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Zentalis Pharmaceuticals Business Overview & Revenue Model
Company Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Zentalis has historically generated little to no recurring product revenue because it has not broadly commercialized an approved drug; as a result, its ability to generate revenue from product sales i...
Zentalis Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -151.00K | 0.00 | 67.42M | 0.00 | 0.00 | 0.00 |
| EBITDA | -173.46M | -144.27M | -186.17M | -247.60M | -233.58M | -207.20M |
| Net Income | -174.90M | -137.06M | -165.84M | -292.19M | -236.81M | -158.72M |
Balance Sheet | ||||||
| Total Assets | 215.33M | 288.97M | 430.34M | 562.03M | 553.46M | 472.02M |
| Cash, Cash Equivalents and Short-Term Investments | 174.61M | 245.89M | 371.08M | 482.92M | 437.37M | 340.13M |
| Total Debt | 37.69M | 39.58M | 42.65M | 45.77M | 47.33M | 45.91M |
| Total Liabilities | 71.68M | 72.76M | 93.15M | 124.64M | 119.43M | 107.54M |
| Stockholders Equity | 143.65M | 216.20M | 337.19M | 437.28M | 433.80M | 363.95M |
Cash Flow | ||||||
| Free Cash Flow | -161.12M | -125.25M | -171.08M | -208.41M | -166.30M | -160.20M |
| Operating Cash Flow | -161.05M | -125.25M | -170.86M | -207.82M | -163.75M | -154.09M |
| Investing Cash Flow | 150.82M | 131.62M | 176.56M | -44.46M | -114.18M | -18.11M |
| Financing Cash Flow | -6.65M | -4.28M | 108.00K | 237.30M | 261.04M | 178.52M |
Zentalis Pharmaceuticals Technical Analysis
Negative
3.88
Price Trends
2.98
Negative
3.65
Negative
3.46
Negative
Market Momentum
-0.26
Negative
31.73
Neutral
9.80
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZNTL, the sentiment is Negative. The current price of 3.88 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.98, and above the 200-day MA of 3.46, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 31.73 is Neutral, neither overbought nor oversold. The STOCH value of 9.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZNTL.
Zentalis Pharmaceuticals Risk Analysis
Zentalis Pharmaceuticals disclosed 81 risk factors in its most recent earnings report. Zentalis Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zentalis Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $64.64M | 7.93 | 16.17% | 0.52% | 26.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $114.72M | -10.82 | -70.44% | ― | ― | 10.04% | |
46 Neutral | $188.40M | -0.81 | -87.95% | ― | -100.00% | 14.08% | |
46 Neutral | $346.26M | -0.72 | 187.62% | ― | -8.79% | -195.46% | |
43 Neutral | $151.61M | -10.82 | -31.27% | ― | 1.32% | 59.94% | |
41 Neutral | $7.58M | -0.10 | -152.59% | ― | ― | ― |
* Healthcare Sector Average
ZNTL
Zentalis Pharmaceuticals
1.99
0.51
34.46%
MGNX
MacroGenics
2.38
0.78
49.22%
VTGN
VistaGen Therapeutics
0.17
-3.58
-95.47%
ANIX
Anixa Biosciences
3.30
-0.76
-18.72%
SPRO
Spero Therapeutics
1.11
-1.25
-52.97%
SRZN
Surrozen
29.46
15.81
115.82%
Zentalis Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Zentalis Pharmaceuticals Announces Major Common Stock Offering
Positive
Aug 14, 2026
On August 13, 2026, Zentalis Pharmaceuticals entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer Co. Inc. for a public offering of 23,000,000 shares of common stock at $3.50 per share, w...
Business Operations and StrategyFinancial Disclosures
Zentalis Highlights Q2 Results and Azenosertib Progress
Positive
Aug 6, 2026
On August 6, 2026, Zentalis Pharmaceuticals reported its second-quarter 2026 results and detailed progress in late-stage development of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. As of June 30, 2026, the company held $17...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.